The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Differentiation Therapy Of Acute Myeloid Leukaemia: Combining RAR-agonists And G-CSF.
Funder
National Health and Medical Research Council
Funding Amount
$449,500.00
Summary
The application of cancer treatments that target specific molecules hold significant promise. However to apply these treatments detailed knowledge is required of the how the molecular targets function in cells. Our previous work using normal blood cells has identified two genes ( MAD1 and p27KIP1 ) that are required for the effects of one such targeted treatment that is aimed at the retinoic acid receptor alpha. We propose to test this treatment in mouse models of human leukaemia and in human le ....The application of cancer treatments that target specific molecules hold significant promise. However to apply these treatments detailed knowledge is required of the how the molecular targets function in cells. Our previous work using normal blood cells has identified two genes ( MAD1 and p27KIP1 ) that are required for the effects of one such targeted treatment that is aimed at the retinoic acid receptor alpha. We propose to test this treatment in mouse models of human leukaemia and in human leukemia cells grown in the laboratory. By deleting the genes for MAD1 and p27KIP1 we will determine if leukaemias lacking these genes fail to respond to treatments targeting the retinoic acid receptor alpha. We will also test if treatments that target retinoic acid receptors in combination with G-CSF, a protein that has previously been demonstrated to have anti-leukaemic activity, can work together to block growth of leukaemic and genetically modified cells. Together these studies will help define classes of leukamias that either will or will not respond to treatments aimed at retinoic acid receptor to better target future leukemia treatments.Read moreRead less
Characterization Of Novel Inhibitors Of G1-S Phase Progression In Drosophila
Funder
National Health and Medical Research Council
Funding Amount
$456,000.00
Summary
Cancer is a disease that affects 1-3 people and therefore, understanding the mechanisms by which cancer arises is of major importance to medical science. Cancers arise through the accumulation of mutations that alter normal cell proliferation control, differentiation, cell death or cell movement. Many genes involved in cancer have been identified, however, there are likely to be many more genes, that when disrupted or misexpressed can lead to cancer. We are interested in the regulation of cell p ....Cancer is a disease that affects 1-3 people and therefore, understanding the mechanisms by which cancer arises is of major importance to medical science. Cancers arise through the accumulation of mutations that alter normal cell proliferation control, differentiation, cell death or cell movement. Many genes involved in cancer have been identified, however, there are likely to be many more genes, that when disrupted or misexpressed can lead to cancer. We are interested in the regulation of cell proliferation, and have been studying this in the genetically amenable animal model system, the vinegar fly, Drosophila. A key regulator of cell proliferation in all multicellular organisms is Cyclin E, which is required to drive cells from the G1 (resting state) into S phase (where DNA replication occurs). Correct control of Cyclin E is important in limiting cell proliferation and many cancer-causing mutations result in up-regulation of this critical cell cycle regulator. We have used a genetic approach to identify novel negative regulators of Cyclin E. This proposal seeks to further clarify the mechanism by which the identified Cyclin E interactors regulate cell cycle progression. In addition, this proposal seeks to identify the genes encoding other cyclin E interactors, expected to be novel tumor suppressors. The expected outcome of this project is to elucidate novel genes and mechanisms that control cell proliferation in the context of a whole organism. Due to the conservation of cell proliferation and signalling proteins, this proposal is relevant to understanding human cancer.Read moreRead less
The Role Of Clathrin In The Spindle Assembly Checkpoint And As An Anti-cancer Target
Funder
National Health and Medical Research Council
Funding Amount
$651,768.00
Summary
Cell division produces two daughter cells. Incorrect localisation and modification of proteins that regulate mitosis cause errors that can lead to cancer. As well as using a unique machinery mitosis uses proteins involved in non-cell cycle pathways. This project investigates the role during mitosis of one such protein: clathrin. We will identify lead clathrin inhibitory compounds, pitstops, that have potential anti-cancer properties, ultimately to be used as a chemotherapy agent.
Molecular Mechanisms Of Mitotic Progression And The Anti-cancer Properties Of Anti-mitotic Agents
Funder
National Health and Medical Research Council
Funding Amount
$466,492.00
Summary
Mitosis is the final stage of the cell division cycle that produces two daughter cells. Incorrect localisation and modification of proteins that regulate this process cause cell division errors potentially leading to cancer. This project will characterise how key mitotic proteins co-operatively function to complete this process. This research will increase our understanding of the cell division errors that contribute to cancer development, ultimately identifying new targets for cancer therapy.
Development Of A Novel And Highly Selective CDK4/6 Inhibitor For Treating Cancer
Funder
National Health and Medical Research Council
Funding Amount
$1,171,199.00
Summary
We have identified and patented novel drug molecules targeting enzymes namely CDKs 4 and 6, that are important for survival of cancer cells. The drugs are highly selective and potent against CDK4/6, well absorbed orally, and have attracted much interest from a pharmaceutical company. Further detailed work is needed to characterize fully their anti-cancer effects and toxicity, thereby securing a major investment from our commercial partner for drug development for treating cancers.
Discovery Of New Targets For Therapy That Kills Non-dividing Cancer Stem Cells
Funder
National Health and Medical Research Council
Funding Amount
$375,828.00
Summary
I am a clinical haematologist that specialises in treating patients with a terrible form of blood cancer, acute myeloid leukaemia. Survival rates for this disease have not changed for 30 years and we now realise this is because we are not targetting the queen bee of the cancer - the cancer stem cell. In this project I am looking for cell markers that are only present in rare, truly latent non-dividing cancer stem cells effectively change a remission into a cure.
Aurora Kinase: Molecular, Cellular And Functional Studies Deciphering Its Role In Stroke Injury
Funder
National Health and Medical Research Council
Funding Amount
$580,993.00
Summary
In stroke patients, oxygen deprivation indirectly induces massive nerve cell death by activating an enzyme called aurora kinase A (AURKA). We aim at unravelling (i) how AURKA is activated by oxygen deprivation, (ii) where the activated AURKA is localised in cells, and (iii) how the activated AURKA induces nerve cell death.The study will benefit development of therapeutic strategies to protect against brain damage in stroke since this is novel and different target for drug targeting.
Regulators Of Cell Cycle As Therapeutic Drug-targets For Cortical Tubular Hyperplasia In Proteinuric Renal Disease
Funder
National Health and Medical Research Council
Funding Amount
$219,750.00
Summary
Currently in Australia, it has been estimated that approximately 60 000 people suffer from chronic kidney failure (CKF). In at least 80% of people with CKF, the kidney function will continue to worsen (due to disease progression) to the point where end-stage kidney failure (ESKF) has developed. When the latter occurs daily treatment by either dialysis or kidney transplantation is mandatory for a person to survive. At present, there are nearly 10 000 patients with ESKF who are being treated by di ....Currently in Australia, it has been estimated that approximately 60 000 people suffer from chronic kidney failure (CKF). In at least 80% of people with CKF, the kidney function will continue to worsen (due to disease progression) to the point where end-stage kidney failure (ESKF) has developed. When the latter occurs daily treatment by either dialysis or kidney transplantation is mandatory for a person to survive. At present, there are nearly 10 000 patients with ESKF who are being treated by dialysis or transplantation, in Australia. Although these treatments have allowed patients to survive, they are associated with significant and unacceptable patient morbidity and mortality. Current medical treatments to reduce the disease progression of CKF (and thereby extend the time taken to reach ESKF) are non-specific, partially effective and have a variable response. Also, these treatments are NOT known to arrest the progression of CKF. To compound the overall problem even further, the number of new patients starting chronic dialysis programmes is increasing (by 6% per year). Consequently, ESKF has been described by leading authorities as a medical catastrophe of world-wide dimensions, and research into ways to reduce-arrest the progression of CKF has been recommended as an urgent priority by the Australian Kidney Foundation. In CKF, the kidneys undergo compensatory growth which is harmful and paradoxically contributes to disease progression. The aim of this research program is to advance knowledge about the molecular mechanisms of kidney growth in CKF, with specific goals of: (i) identifying new molecular targets for drug-based manipulation of kidney growth; and (ii) to test the efficacy of experimental drugs which have an ability to alter kidney growth, and thereby reduce the progression of CKF.Read moreRead less
HFP ACTIVATES PROTEOLYSIS OF POSITIVE CELL CYCLE REGULATORS TO INHIBIT CELL CYCLE PROGRESSION IN DROSOPHILA
Funder
National Health and Medical Research Council
Funding Amount
$438,750.00
Summary
Cell proliferation is essential for animal development and tissue regeneration. In order to proliferate, cells must double their DNA contents and segregate their chromosomes precisely into daughter cells. Collectively this series of events is referred to as the Cell Cycle. The cell cycle must be carefully regulated since inappropriate proliferation can cause developmental abnormalities and tumour formation in multicellular animals. Proliferation is regulated by a balanced set of interactions bet ....Cell proliferation is essential for animal development and tissue regeneration. In order to proliferate, cells must double their DNA contents and segregate their chromosomes precisely into daughter cells. Collectively this series of events is referred to as the Cell Cycle. The cell cycle must be carefully regulated since inappropriate proliferation can cause developmental abnormalities and tumour formation in multicellular animals. Proliferation is regulated by a balanced set of interactions between two group of proteins, cell cycle activators and cell cycle inhibitors. Aberrations in cell cycle inhibitor proteins will cause excessive cell proliferation, the first step in the multi-step process of tumour development. It is important to understand the processes that normally inhibit cell proliferation, since cells undergoing more rapid cell cycles are much more likely to develop further errors in their genetic material and progress to later stage invasive tumours. This proposal focuses on a protein (FIR-Hfp) that we have shown to inhibit cell cycle progression in the vinegar fly (Drosophila Melanogaster), which is an excellent model organism for studying developmentally regulated cell proliferation. Furthermore, most cell cycle regulators are conserved in evolution, so the knowledge derived from these studies can assist with our understanding of how complex pathways might coordinate proliferation mammals. FIR-Hfp negatively regulates cell proliferation by down-regulating cycle activator proteins (dMyc and Stg). At present the mechanism for the inhibitory affect on these activators is not understood, but preliminary data suggests that FIR-Hfp might be involved in causing Stg and the dMyc activator protein (Hay) to be targeted for destruction. The aim of this project is to elucidate the mechanism by which Hfp regulates the activity of these potentially ocogenic factors, and thus gain a better understanding of the preliminary stages of tumour progression.Read moreRead less